EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport

Oliver Gross iD, Jan Boeckhaus, Lutz T Weber, Hiddo J L Heerspink iD, James F Simon, Rees Ahmed, Christoph Gerst, Ulrike Duerr, Florian Walker, Ralf Tostmann, Jürgen Helm, Thomas Asendorf und 2 weitere

Nephrology Dialysis Transplantation · 01.04.2025 · 40 (4) · 679-687

DOI: 10.1093/ndt/gfae180 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 09.08.2024. Verfasst von Oliver Gross und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany. Hauptthemen laut MEDLINE: Albuminuria, Benzhydryl Compounds, Glucosides, Nephritis, Hereditary. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EU, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium–glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs). Whether benefits extend to children, teenagers and young adults with early-stage CKD is unknown. For this reason, the DOUBLE PRO-TECT Alport trial (NCT05944016) will study the progression of albuminuria in young patients with Alport syndrome (AS), the most common hereditary CKD, to assess the safety and efficacy of the SGLT2 inhibitor dapagliflozin. Patients living with AS and chronically elevated albuminuria have a high risk of kidney failure before the age of 50 years.

Methods

DOUBLE PRO-TECT Alport is a multicentre, randomized, double-blind, placebo-controlled trial.

Participants

(ages 10–39 years) must have a diagnosis of AS by genetic testing or kidney biopsy, be on a stable (>3 months) maximum tolerated dose of a renin–angiotensin system inhibitor and have a urinary albumin:creatinine ratio (UACR) of >300 mg/g (paediatric) or >500 mg/g (adult). Eligible participants will be randomly assigned at a 2:1 ratio to 48 weeks of treatment with dapaglifozin 10 mg/day or matched placebo. Most participants are expected to be children with a normal estimated glomerular filtration rate (eGFR). In addition to safety, the primary (change in UACR from baseline to week 48) and key secondary (eGFR change from baseline to week 52) efficacy outcomes will be analysed with a mixed model repeated measures approach. Efficacy analyses will be performed primarily in the full analysis set according to the intention-to-treat principle. A sensitivity analysis will be performed using reference-based multiple imputation.

Conclusion

DOUBLE PRO-TECT Alport will assess whether SGLT2 inhibitors can safely reduce the UACR change from baseline as a marker for progression of CKD in young patients living with AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaBenzhydryl CompoundsGlucosidesNephritis, HereditaryRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAdolescentAdultChildFemaleHumansMaleYoung AdultDouble-Blind MethodFollow-Up StudiesGlomerular Filtration RatePrognosisRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

Alport syndromeSGLT2 inhibitordapagliflozinempagliflozinpaediatric trial

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
  • Pediatric Nephrology, Children's and Adolescents' Hospital, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Legal Department, University Medical Center Göttingen, Göttingen, Germany.
  • Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany.

ORCID-Profile: Oliver Gross, Hiddo J L Heerspink, Tim Friede

Förderung

  • EU
  • German Research Foundation

Zitieren

APA

Gross, O., Boeckhaus, J., Weber, L. T., Heerspink, H. J. L., Simon, J. F., Ahmed, R., Gerst, C., Duerr, U., Walker, F., Tostmann, R., Helm, J., Asendorf, T., Friede, T., & study group of the German Society of Pediatric Nephrology (2025). Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrology Dialysis Transplantation, 40(4), 679-687. https://doi.org/10.1093/ndt/gfae180

Vancouver

Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, et al. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrology Dialysis Transplantation. 2025;40(4):679-687. doi:10.1093/ndt/gfae180

BibTeX
@article{Gross2025,
  author = {Gross, Oliver and Boeckhaus, Jan and Weber, Lutz T and Heerspink, Hiddo J L and Simon, James F and Ahmed, Rees and Gerst, Christoph and Duerr, Ulrike and Walker, Florian and Tostmann, Ralf and Helm, Jürgen and Asendorf, Thomas and Friede, Tim and study group of the German Society of Pediatric Nephrology, study group of the German Society of Pediatric Nephrology},
  title = {Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {4},
  pages = {679--687},
  doi = {10.1093/ndt/gfae180}
}
Kostenlos starten →